{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:46:55Z","timestamp":1772081215991,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIdelalisib in combination with rituximab is an efficacious treatment for patients suffering from chronic lymphocytic leukemia (CLL) with known limitations due to toxicities. However, the benefit after prior Bruton tyrosine kinase inhibitor (BTKi) therapy remains unclear. For this analysis, 81 patients included in a non-interventional registry study of the German CLL study group (registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link> as # NCT02863692) meeting the predefined criteria of a confirmed diagnosis of CLL and being treated with idelalisib containing regimens outside clinical trials were considered. 11 patients were treatment na\u00efve (13.6%) and 70 patients (86.4%) pretreated. Patients had median of one prior therapy line (range 0\u201311). Median treatment duration with idelalisib was 5.1\u00a0months (range 0\u201355.0\u00a0months). Of 58 patients with documented treatment outcome, 39 responded to idelalisib containing therapy (67.2%). Patients treated with the BTKi ibrutinib as last prior treatment prior to idelalisib responded in 71.4% compared to a response rate of 61.9% in patients without prior ibrutinib. Median event free survival (EFS) was 15.9\u00a0months with a 16 versus 14\u00a0months EFS in patients with ibrutinib as last prior treatment or not, respectively. Median overall survival was 46.6\u00a0months. In conclusion, treatment with idelalisib appears to have a valuable impact in patients being refractory to prior ibrutinib therapy even though there are limitations in our analysis due to the low number of patients included.<\/jats:p>","DOI":"10.1007\/s00277-023-05314-2","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T05:01:43Z","timestamp":1687755703000},"page":"3083-3090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment with idelalisib in patients with chronic lymphocytic leukemia \u2013 real world data from the registry of the German CLL Study Group"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-4603","authenticated-orcid":false,"given":"Julia","family":"von Tresckow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Heyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Robrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Giza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Aldaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Klausmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Linde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"issue":"11","key":"5314_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997\u20131007","journal-title":"N Engl J Med"},{"issue":"16","key":"5314_CR2","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP et al (2019) Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 37(16):1391\u20131402","journal-title":"J Clin Oncol"},{"issue":"1","key":"5314_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.17475","volume":"194","author":"TA Eyre","year":"2021","unstructured":"Eyre TA et al (2021) A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel). Br J Haematol 194(1):69\u201377","journal-title":"Br J Haematol"},{"issue":"4","key":"5314_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000692","volume":"6","author":"N Kutsch","year":"2022","unstructured":"Kutsch N et al (2022) Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere 6(4):e692","journal-title":"Hemasphere"},{"issue":"5","key":"5314_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","volume":"28","author":"AR Mato","year":"2017","unstructured":"Mato AR et al (2017) Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 28(5):1050\u20131056","journal-title":"Ann Oncol"},{"issue":"5","key":"5314_CR6","first-page":"3025","volume":"38","author":"B Pula","year":"2018","unstructured":"Pula B et al (2018) Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed\/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). Anticancer Res 38(5):3025\u20133030","journal-title":"Anticancer Res"},{"issue":"5","key":"5314_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/ejh.13499","volume":"105","author":"K Aarup","year":"2020","unstructured":"Aarup K et al (2020) Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Eur J Haematol 105(5):646\u2013654","journal-title":"Eur J Haematol"},{"issue":"9","key":"5314_CR8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR et al (2018) Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103(9):1511\u20131517","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05314-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05314-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05314-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:14:06Z","timestamp":1697019246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05314-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5314"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05314-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The registry study of the German CLL study group was approved by all involved Ethic committees according to the declaration of Helsinki and German physicians\u2019 professional regulation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"All patients provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Julia von Tresckow: reports travel support by AbbVie, AstraZeneca, Beigene, Janssen, Lilly and Roche and is an advisor or consultant for AbbVie, Amgen, AstraZeneca, Beigene, Janssen and Roche; has received honoraria from AbbVie, AstraZeneca, Beigene, Janssen, Lilly and Roche.Nikola Heyl, Sandra Robrecht, Adam Giza, Ali Aldaoud and Rudolf Schlag: have nothing to disclose.Martine Klausmann: reports consultancy for Biotest and has received honoraria by BMS, Novartis, Abvie, Biotest, Octapharm and Geron.Hartmut Linde: has received honoraria by Mundipharma and is an advisor for Amgen, Novartis and Mundipharma and reports travel support by Servier, Novartis, Janssen, Abbvie, BMS.Wolfgang Stein and Andreas Schwarzer: have nothing to disclose.Kirsten Fischer: reports honoraria by AbbVie and Roche and is an advisor for AstraZeneca.Paula Cramer: reports research funding by Acerta, AstraZeneca, Beigene, F. Hoffmann-LaRoche, Gilead, Janssen-Cilag and Novartis and has received honoraria from AbbVie, AstraZeneca, F. Hoffmann-LaRoche and Janssen-Cilag; is an advisor for AbbVie, AstraZeneca and BeiGene and received travel support by AbbVie, AstraZeneca, BeiGene, and F. Hoffmann LaRoche.Barbara Eichhorst is an advisor or consultant for Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, AstraZeneca, MSD and\u00a0Miltenyi and received honoraria from Janssen, Gilead, Roche, AbbVie, Novartis, Celgene, AstraZeneca,\u00a0BeiGene and MSD; reports research funding by Janssen, Gilead, Roche, AbbVie,\u00a0BeiGene and Astra\u00a0Zeneca.Michael Hallek: is an advisor or consultant for Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie and AstraZeneca and reports honoraria from Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie and AstraZeneca. Anna Maria Fink: reports research funding by AstraZeneca and Celgene and travel support by AbbVie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}}]}}